Published in Diabetes Technol Ther on November 15, 2013
Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig (2015) 1.96
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering. J Clin Med Res (2015) 1.07
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther (2014) 0.97
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol (2016) 0.96
Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring. J Diabetes Investig (2015) 0.82
Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes (2015) 0.81
The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract (2015) 0.79
Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence. Indian J Endocrinol Metab (2016) 0.79
Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. Indian J Endocrinol Metab (2015) 0.79
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol (2016) 0.77
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs Aging (2016) 0.76
Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.75
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther (2014) 0.75
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol (2017) 0.75
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med (2003) 8.00
Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes (2002) 7.17
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med (2004) 5.49
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat (2005) 4.14
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med (2004) 2.51
Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc (2008) 2.26
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med (2009) 2.02
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 1.85
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol (2005) 1.76
Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care (2009) 1.75
Adiponectin in health and disease. Diabetes Obes Metab (2007) 1.64
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril (2007) 1.63
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med (2013) 1.55
Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab (2004) 1.55
A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med (2004) 1.53
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Crystallographic structure of the K intermediate of bacteriorhodopsin: conservation of free energy after photoisomerization of the retinal. J Mol Biol (2002) 1.51
Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers. Mayo Clin Proc (2013) 1.50
Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes (2006) 1.50
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin. Anesthesiology (2004) 1.42
Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest (2010) 1.39
Investigating interpersonal competencies of cardiac surgery teams. Can J Surg (2006) 1.35
Scrub typhus meningitis in South India--a retrospective study. PLoS One (2013) 1.34
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract (2003) 1.26
Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care (2003) 1.25
Quality performance measurement using the text of electronic medical records. Med Decis Making (2008) 1.24
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc (2003) 1.22
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Outpatient weight management in African-Americans: the Healthy Eating and Lifestyle Program (HELP) study. Prev Med (2005) 1.14
Effect of high protein vs high carbohydrate intake on insulin sensitivity, body weight, hemoglobin A1c, and blood pressure in patients with type 2 diabetes mellitus. J Am Diet Assoc (2005) 1.14
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. Diabetes (2012) 1.08
Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res (2007) 1.08
RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol (2006) 1.08
Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci (2011) 1.08
Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab (2005) 1.07
Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther (2008) 1.07
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes (2002) 1.06
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. Am J Cardiol (2010) 1.05
Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response. Infect Immun (2005) 1.05
Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res (2005) 1.04
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care (2002) 1.03
Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets (2006) 1.03
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res (2011) 1.02
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes (2009) 1.02
Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med (2010) 1.01
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte (2013) 1.01
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med (2013) 1.00
Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985) (2010) 0.99
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev (2006) 0.98
Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists [corrected]. Bioorg Med Chem Lett (2004) 0.98
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol (2004) 0.98
Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep (2002) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Single nucleotide polymorphism (SNP) discovery in mammals: a targeted-gene approach. Mol Ecol (2004) 0.97
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab (2006) 0.97
The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine (2008) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab (2005) 0.95
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab (2010) 0.95
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2003) 0.94
Incretin therapies: effects beyond glycemic control. Am J Med (2009) 0.93
The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose-lipid metabolism in vitro. Mol Cell Endocrinol (2011) 0.93
Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS One (2012) 0.93
Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity. Eur J Endocrinol (2011) 0.93
MK-0536 inhibits HIV-1 integrases resistant to raltegravir. Antimicrob Agents Chemother (2011) 0.93
Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins. Hepatology (2010) 0.92
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism (2003) 0.92
Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol (2010) 0.91
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A (2012) 0.91
Value of electrocardiographic and ankle-brachial index abnormalities for prediction of coronary atherosclerosis in asymptomatic subjects with type 2 diabetes mellitus. Am J Cardiol (2007) 0.91
Diabetic muscle infarction of the forearm in a patient with long-standing type 1 diabetes. Endocr Pract (2006) 0.91
Free fatty acids, insulin resistance, and pregnancy. Curr Diab Rep (2003) 0.91
GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int (2013) 0.90
Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism (2003) 0.90
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90